The co-administration of MPT0E028 and mitogen-activated protein kinase (MEK) inhibitors has synergistic effects in KRAS-mutated and KRAS-wild-type pancreatic cancer cells. The gene discussed is MAP2K7; the disease is familial pancreatic carcinoma.